highlighted below; (Unit : Million Baht) Separate financial statements Q3/2018 Q3/2017 % Change Sales and Service income 462 514 (10) Cost of Sales and Services 363 405 (12) Selling and Administrative Expenses

THB 12.02 million, compared to the same quarter in 2019, the operating result decreased THB 11.29 million or 1,535.92 per cent. 1. Income from service and commission of the consolidated financial

35.74 Total liabilities 209.95 219.14 226.79 Shareholders’ equity Registered 10.00 86.00 86.00 Issued and fully paid-up 10.00 86.00 86.00 Retained earnings (deficit) 34.78 50.35 76.10 Total shareholders

2% (6) (19%) Income tax expenses 17 1% 34 2% (17) (50%) Selling expenses Selling expenses for the third quarter of 2019 and the selling expenses to revenue from main business were not significant

Quarter Ending September 30, 2017) (1) Overall Operating Results For the 3rd quarter 2017, the total revenue from sales and services of the Company and its subsidiary (together referred to as the “Corporate

medicines, expanding various product types, increasing revenue and reducing costs Agenda 4 To consider and approve the issuance and offering of debentures in an amount not exceeding 300 million Baht. The

as follows. The total revenue of the Company and its subsidiaries in the consolidated financial statements for the year 2017 was equal to 762.85 million Baht, an increase of 148.67 million Baht or

the performance of the company and its subsidiaries in accordance with Comprehensive Income Statement In The year 2018, the company has net loss of 189.21 million baht, compared to the same period of

of Baht 11 million for the quarter ended 30th June 2019 and 2018. The decrease of Baht 9.55 million in the profit is mainly due to the following. 1. The decrease in the Group’s revenue 3.29% or Baht

significant results are as follows: Consolidated sales and service income for the second quarter 2019 was 175.9 million baht compared to 310.5 million baht the same period last year, decreased 134.6 million